BCPS Regulatory Practice Test

Promoting safe and effective medicines for children relies on combining regulatory requirements with incentives to study drugs in pediatric populations. The Pediatric Research Equity Act requires sponsors to study new drugs in children and to include pediatric data in labeling unless a deferral or waiver is granted, ensuring that pediatric use is evaluated and documented. The Best Pharmaceuticals for Children Act provides incentives—most notably a potential six-month extension of market exclusivity—for sponsors who complete pediatric studies in response to FDA-issued requests, and it supports updating labeling with pediatric information. Together, these acts create a framework that both obligates and rewards pediatric research, improving the availability and safety of medicines for children. Other options address areas outside pediatric drug development: the Orphan Drug Act targets rare diseases, while the Food Additives Amendment and the Dietary Supplement Health and Education Act govern safety and labeling for foods and dietary supplements, not pediatric drug development.